{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:16Z","timestamp":1788415936308,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Objective<\/jats:title>\n \n To report the identification of a\n FGFR3<\/jats:italic>\n gene variant in a family with idiopathic short stature, characterized by proportionate stature and the absence of dysmorphic features, and to highlight the importance of genetic investigation in ISS as well as the clinical heterogeneity of the\n FGFR3<\/jats:italic>\n N540S variant.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Based on clinical and genetic data collected from the proband and short-statured relatives, we analyzed the clinical characteristics of the pedigree and the pathogenicity of the genetic variant.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A 3-year-old male presented with proportionate short stature and no dysmorphic features. Imaging studies revealed no significant skeletal abnormalities. Combined with the short stature observed in multiple family members, a clinical diagnosis of FSS was established. Whole-exome sequencing identified a maternally inherited heterozygous\n FGFR3<\/jats:italic>\n variant (c.1619A&gt;G, p.N540S) in the proband. The mother and maternal grandfather also harbored this variant. ACMG classification deemed it likely pathogenic. Literature review revealed that all previously reported patients with the\n FGFR3<\/jats:italic>\n N540S variant exhibited clinical manifestations of HCH with abnormal radiographic features.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This is the first report of proportionate short stature associated with the\n FGFR3<\/jats:italic>\n N540S variant, demonstrating substantial phenotypic heterogeneity at this site. Genetic testing is strongly recommended for patients with FSS, particularly those with severe short stature.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1881876","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:13:35Z","timestamp":1788412415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Proportionate short stature in a three-generation family harboring FGFR3 N540S: phenotypic expansion beyond hypochondroplasia and implications for genetic screening in idiopathic short stature"],"prefix":"10.3389","volume":"17","author":[{"given":"Beibei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjie","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13052-021-01018-3","article-title":"Definition and prevalence of familial short stature","volume":"47","author":"Grigoletto","year":"2021","journal-title":"Ital J Pediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.19538\/j.ek2023110601","article-title":"Chinese expert consensus on the diagnosis and treatment of children with idiopathic short stature","volume":"38","year":"2023","journal-title":"Chin J Pract Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn339","article-title":"FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway","volume":"18","author":"Matsushita","year":"2009","journal-title":"Hum Mol Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410148200","article-title":"Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis","volume":"280","author":"Davidson","year":"2005","journal-title":"J Biol Chem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/humu.21636","article-title":"Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias","volume":"33","author":"Foldynova-Trantirkova","year":"2012","journal-title":"Hum Mutat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03526-2","article-title":"Pathways to facilitate early recognition and diagnosis of hypochondroplasia","volume":"43","author":"Irving","year":"2026","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.63431","article-title":"Growth reference charts for children with hypochondroplasia","volume":"194","author":"Cheung","year":"2024","journal-title":"Am J Med Genet A"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1364441","article-title":"Clinical profiles and molecular genetic analyses of 98 Chinese children with short statures","volume":"15","author":"Fang","year":"2024","journal-title":"Front Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0945","article-title":"A novel variant of FGFR3 causes proportionate short stature","volume":"172","author":"Kant","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B10","first-page":"77","article-title":"ASN540SER mutation is associated with a mild form of hypochondroplasia: a 7 years follow-up in an Italian boy","author":"De Sanctis","year":"2012","journal-title":"Georgian Med News"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-005-1640-0","article-title":"Disproportionate stature but normal height in hypochondroplasia","volume":"164","author":"Riepe","year":"2005","journal-title":"Eur J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.10238","article-title":"Hypochondroplasia and stature within normal limits: another family with an Asn540Ser mutation in the fibroblast growth factor receptor 3 gene","author":"Thauvin-Robinet","year":"2003","journal-title":"Am J Med Genet A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.37.3.220","article-title":"Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene","volume":"37","author":"Mortier","year":"2000","journal-title":"J Med Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.eprac.2022.04.004","article-title":"Pediatric continuous reference intervals of serum insulin-like growth factor 1 levels in a healthy Chinese children population - based on PRINCE study","volume":"28","author":"Cao","year":"2022","journal-title":"Endocr Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.4.1095","article-title":"Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3","volume":"88","author":"Keegan","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.8.4081","article-title":"Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II","volume":"16","author":"Webster","year":"1996","journal-title":"Mol Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-024-01731-0","article-title":"Functional profiling of serine, threonine and tyrosine sites","volume":"21","author":"Li","year":"2025","journal-title":"Nat Chem Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8132","article-title":"Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use","volume":"7","author":"Patani","year":"2016","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0509","article-title":"Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop","volume":"93","author":"Cohen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1297\/cpe.2021-0044","article-title":"History of GH treatment in Japan","volume":"31","author":"Tanaka","year":"2022","journal-title":"Clin Pediatr Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.15.129","article-title":"Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis","volume":"16","author":"Massart","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.0043","article-title":"Evaluation of efficacy of long-term growth hormone therapy in patients with hypochondroplasia","volume":"10","author":"\u00c7etin","year":"2018","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102591","article-title":"Vosoritide treatment for children with hypochondroplasia: a phase 2 trial","volume":"71","author":"Dauber","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1881876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:13:42Z","timestamp":1788412422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1881876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":23,"alternative-id":["10.3389\/fendo.2026.1881876"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1881876","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1881876"}}